NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.00
+2.90%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.22
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.30
- EPS estimate
- -$0.26
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -25.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $36
- PT range
- $33 – $39
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.26 | -$0.30 | Miss -14.50% | — |
| May 5, 2026 | -$0.30 | -$0.26 | Beat 13.33% | — |
| Feb 11, 2026 | -$0.26 | -$0.31 | Miss -19.23% | — |
| Nov 4, 2025 | -$0.24 | -$0.44 | Miss -83.33% | — |
| Feb 25, 2025 | -$0.28 | -$0.36 | Miss -28.57% | — |
| Mar 5, 2024 | -$0.40 | -$0.41 | Miss -2.50% | -$4.1M |
| Mar 7, 2023 | -$0.38 | -$0.48 | Miss -26.32% | $149.0K |
| Aug 5, 2022 | -$0.24 | -$0.28 | Miss -16.67% | -$140 |
| Feb 7, 2022 | -$0.85 | -$0.18 | Beat 79.08% | $4.0K |
| Jun 30, 2021 | — | -$0.47 | — | — |
| Mar 31, 2021 | — | -$0.00 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026